Intra-Cellular Therapies, Inc. filed a Form 8-K on March 3, 2025, providing an update on its pending merger with Johnson & Johnson. The company announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on February 26, 2025, satisfying one of the conditions for closing the merger. The transaction remains subject to customary closing conditions, including shareholder approval.

A special meeting of stockholders is scheduled for March 27, 2025, to vote on the merger agreement. Additional details, including the merger terms, are available in the definitive proxy statement filed with the SEC on February 18, 2025. The company advises stockholders to review all relevant documents before making voting decisions.